Dermira Inc. (NASDAQ:DERM) shares traded up 2% during trading on Monday . The company traded as high as $32.78 and last traded at $32.63, with a volume of 79,001 shares. The stock had previously closed at $32.00.

A number of research analysts have commented on the stock. Zacks Investment Research cut shares of Dermira from a “hold” rating to a “sell” rating in a research note on Tuesday, May 3rd. Leerink Swann restated a “buy” rating and set a $47.00 price target (up previously from $46.00) on shares of Dermira in a research note on Thursday, June 2nd. Needham & Company LLC restated a “buy” rating and set a $42.00 price target (up previously from $38.00) on shares of Dermira in a research note on Tuesday, May 10th. Finally, Wedbush raised their price target on shares of Dermira from $42.00 to $46.00 and gave the stock an “outperform” rating in a research note on Thursday, June 2nd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Dermira has an average rating of “Buy” and a consensus price target of $41.00.

The stock’s 50-day moving average price is $31.49 and its 200-day moving average price is $27.01. The stock’s market capitalization is $1.17 billion.

Dermira (NASDAQ:DERM) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.86) by $0.03. On average, equities analysts forecast that Dermira Inc. will post ($3.39) EPS for the current fiscal year.

In other news, VP Christopher M. Griffith sold 1,303 shares of the business’s stock in a transaction dated Friday, July 15th. The shares were sold at an average price of $30.02, for a total transaction of $39,116.06. Following the transaction, the vice president now directly owns 44,941 shares in the company, valued at approximately $1,349,128.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Christopher M. Griffith sold 4,405 shares of the business’s stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $30.16, for a total transaction of $132,854.80. Following the transaction, the vice president now owns 48,043 shares in the company, valued at $1,448,976.88. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Dermira stock. Jennison Associates LLC increased its position in shares of Dermira Inc. (NASDAQ:DERM) by 8.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,097,201 shares of the biopharmaceutical company’s stock after buying an additional 83,858 shares during the period. Jennison Associates LLC owned approximately 3.67% of Dermira worth $37,974,000 at the end of the most recent quarter.

Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.